Trial Profile

Phase Ib Trial Of Pembrolizumab And Nintedanib

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Malignant-mesothelioma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
Focus Adverse reactions
Acronyms PEMBIB

Most Recent Events

24 Apr 2023 Planned number of patients changed from 18 to 221.
24 Apr 2023 Planned End Date changed from 1 Jul 2026 to 1 Nov 2028.
24 Apr 2023 Planned primary completion date changed from 1 Jul 2021 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com